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Background & aims: Hepatitis B virus (HBV) RNA can undergo alternative splicing but the 
relevance of this post-transcriptional regulation remains elusive. Here, the mechanism of 
HBV alternative splicing regulation and its impact on liver pathogenesis were investigated.  
Methods: HBV RNA-interacting proteins were identified by RNA pull-down combined to 
mass spectrometry analysis. HBV splicing regulation was investigated in chemically and 
surgically induced liver damage in whole HBV genome transgenic mice and in hepatoma 
cells. Viral and endogenous gene expression were quantified by RT-qPCR, western blot and 
ELISA. Resident liver immune cells were studied by FACS.  
Results: HBV pregenomic RNA-interacting proteins were identified and 15% were directly 
related to the splicing machinery. Expression of these splicing factors was modulated in HBV 
transgenic mice under liver injuries and contributed to an increase of the HBV spliced RNA 
encoding for HBV splicing-generated protein (HBSP). HBSP transgenic mice exhibited an 
attenuated hepatic damage under chemically induced liver fibrosis. The protective effect of 
HBSP resulted from a decrease of inflammatory monocyte/macrophage recruitment through a 
downregulation of CCL2 expression produced by hepatocytes. In human hepatoma cells, 
ability of HBSP to control CCL2 expression was confirmed and maintained in a whole HBV 
context. Finally, viral spliced RNA detection related to a decrease of CCL2 expression in 
liver of HBV chronic carriers underscored this mechanism.  
Conclusion: Microenvironment modified by liver injury increased HBSP RNA expression 
through splicing factors regulation, which in turns controlled hepatocyte chemokine 
synthesis. This feedback mechanism suggests a novel insight in liver immunopathogenesis 




































































Lay summary: Hepatitis B virus persists during decades in liver of chronic infected patients. 
One of the main mechanisms developed by this virus to persist is to escape immune response. 
Our study highlights how the crosstalk between virus and liver infected cells may contribute 







































































Constitutive splicing is an essential step for eukaryotic gene expression, generating 
mature mRNAs by removing introns and allowing exons to be joined together accurately. In 
contrast, alternate splicing (including exon skipping, intron retention, alternate 3’ or 5’ splice 
sites) contributes to the diversity of eukaryotic proteome[1] and involves in the control of 
expression of regulatory proteins in the viral context[2]. The splicing process is coordinated 
by the spliceosome, a large ribonucleoprotein complex, on specific RNA domains in 
association with ubiquitous transregulatory splicing factors including serine–arginine-rich 
(SR) and heterogeneous nuclear ribonucleoprotein (hnRNPs) families[3].  
The ability of Hepatitis B Virus (HBV) transcripts to undergo to alternate splicing 
(AS) has been well described in vitro and in the liver of patients with chronic infection 
(CHB)[4, 5]. The 3.5 kb pregenomic RNA (pgRNA) of HBV, which encodes for capsid and 
polymerase proteins, and constitutes the template for viral genome replication, can be 
alternatively spliced[6]. The major pgRNA spliced variant, SP1RNA, has one third of the 
viral genome deleted (“intron 2447/489”) and may account for up to 30% of total HBV 
pgRNA. SP1RNA can be packaged in core particles, reverse-transcribed and secreted. While 
pgRNA packaging leads to wild-type Dane particle secretion (wtHBV), the shorter SP1RNA 
constitutes a matrix for defective HBV circulating particles (dHBV), varying in proportion 
from 0% to more than 50% of HBV forms[7-10]. The regulation of SP1RNA during the 
course of liver disease remains poorly understood. However, recent reports in HBV infected 
patients have shown that the proportion of dHBV relates to viral replication, to interferon 
therapy failure[11] and increases with liver disease progression towards hepatocellular 
carcinoma (HCC)[8, 9]. 
SP1RNA allows the expression of HBV splicing-generated protein (HBSP). HBSP 



































































original viral sequence constituting its C-terminal part (65 amino-acids). HBSP has been 
identified in liver tissues from patients with CHB[12], in whom it can induce an immune 
response[13]. The function of HBSP protein in liver pathogenesis remained uncertain, 
although in vitro studies had suggested an impact on cell viability, proliferation and migration 
[12, 14] and more recently on hacking the TNF-α signaling pathway [15]. 
The previous observation that dHBV particles increase with liver disease progression 
prompted us to investigate whether and how regulation of HBV AS and liver pathogenesis 
are mechanistically linked. Because, the lack of robust animal models of liver pathogenesis 
induced by HBV infection, we decided to investigate the viral post-transcriptional regulation 
in HBV transgenic mice[16]. Here we report that alteration of spliceosome machinery in 
HBV expressing cells is switched on by liver injury and enables a striking reduction in liver 
monocyte/macrophage recruitment through HBSP expression. Our findings reveal a novel 
paradigm whereby AS can generate a viral product able to inhibit immune-mediated 




































































Materials and Methods 
 
Mice and liver pathogenesis models 
Inbred C57BL/6J HBV-transgenic mouse lineage 1.3.32 (TgHBV) has been previously 
described[17]. TgHBV mice express and replicate HBV in the liver under the control of HBc 
promoter/enhancer-II. The two independent transgenic HBSP1 and HBSP2 mice strains carry 
HBSP gene (333 bp) encoding for the HBSP protein under the control of the HBx 
promoter/enhancer I (nt 832/1371)[15]. A rabbit β-globin intron was inserted between the 
HBx promoter/enhancer-I sequence and HBSP gene (genotype A). HBSP1 and HBSP2 
transgenic mice were generated and expanded by back-crossing against the C57BL/6J strain 
(>12 back-crossings). C57BL/6J invalidated for CCR2 gene expression (CCR2KO) mice 
were also used [18]. All experiments were performed on 2-months old, heterozygous 
TgHBV, TgHBSP1, TgHBSP2 or homozygous CCR2 KO and corresponding littermate (WT) 
male mice.  
WT and TgHBV mice were treated for 7 weeks with carbon tetrachloride intraperitoneal 
injections (CCl4, 1ml/kg in oil, Sigma) twice a week to induce chronic liver fibrosis. 
Fulminant liver injury was generated by surgical bile duct ligation (BDL) using double 
sutures of bile duct near liver junction; WT and TgHBV mice were monitored for 2 days 
before sacrifice. Lipopolysaccharide intraperitoneal injections (LPS, 2.5mg/kg, Sigma) three 
times a week for 2 weeks were performed on WT and TgHBV mice to induce liver 
inflammation. TgHBSP, CCR2 KO and corresponding WT mice were treated twice a week 
with CCl4 (1ml/kg in oil, Sigma) for 2 and/or 10 weeks. Acute liver injury was also 
performed in TgHBSP1 mice by a single intraperitoneal injection of CCl4 (1ml/kg in oil). 
Thioacetamide intraperitoneal injections (TAA, 250mg/kg in PBS, Sigma) three times a week 
were performed on WT and TgHBSP1 mice for 2 weeks to induce liver fibrosis. TgHBV, 



































































were perfused with PBS-2% FCS and removed for analysis. Animals were maintained in 
pathogen–free conditions on 12-hour dark/light cycles and treated in accordance with EU 
regulations on animal care (Directive 86/609/EEC). All procedures were approved by the 
local animal care and use committee (Agreement A75-14-08; n° 02890 and 02891). Alanine 
aminotransferase (ALT) in serum was measured on a Cobas® 6000 analyzer (Roche), 
according to the manufacturer’s instructions. 
 
Human HBV infected liver samples 
Patients were recruited from Mustapha Hospital (Alger, Algeria) and The Royal London 
Hospital (London, UK). Full ethical approval was obtained for the study; agreements by the 
National Health Ministry (according to legal article about clinical trials n°387 et 388 of 
31/07/2006) and the Local Ethical Review Board at the Royal London Hospital. All patients 
recruited gave written informed consent. Liver samples, from biopsies surplus to diagnostic 
requirements, were obtained from 12 HBV-monoinfected patients. Patients were anti-HCV, 
anti-HDV and anti-HIV antibody negative and treatment naive. All patients had evidence of 
moderate liver damaged; scored by a pathologist according to the Metavir stage. ALT, 
HBeAg and HBsAg titres were determined using commercial assays (Roche, Biorad and 
Diasorin, respectively). 







































































Increase in HBV alternate splicing upon liver injury 
 To assess whether liver injury impacts on HBV splicing regulation, TgHBV were 
treated with either CCl4 (7 weeks/IP) or LPS (2 weeks/IP) to induce liver fibrosis or 
inflammation, respectively (FigS1 and Fig.S2). The amount of HBV pgRNA was reduced by 
a 5.3 fold and a 3.9 fold in LPS and CCl4 treated TgHBV mice, respectively (Fig.1A) as well 
as HBV viral load (FigS3). In contrast, HBV AS was significantly increased (Fig.1A). 
Indeed, quantification of HBV pgRNA and SP1RNA-derived forms showed a significant 
increase of the SP1RNA proportion in both CCl4 and LPS-treated TgHBV mice compared to 
control mice (oil-TgHBV vs CCl4-TgHBV: 32.5±9.6% vs 49.7±17.2%, p=0.04; PBS-TgHBV 
vs LPS-TgHBV: 27.6±8.7% vs 42.7±10.1%, p=0.01). Additionally, HBV AS upregulation 
was also observed in TgHBV mice with a BDL-induced fulminant hepatitis (control-TgHBV 
vs BDL-TgHBV: 30.6±4.9% vs 69.0±3.0%, p=0.001) (Fig.S4). These results may support an 
influence of liver damage on HBV post-transcriptional regulation. 
Previous clinical studies suggested a correlation of HBV alternative splicing and the 
course of liver disease[8, 9] but the relevance of HBV pgRNA splicing to liver pathogenesis 
remains unknown. We therefore compared liver fibrosis or inflammation following CCl4 or 
LPS treatment of TgHBV and their littermate wild-type (WT) control mice. Despite the well-
known activities of HBV proteins on signaling pathways involved in inflammatory and 
fibrotic processes[19], CCl4-treated TgHBV and WT mice displayed a comparable low stage 
of liver fibrosis (F2) on histological section (Fig.1B). This was confirmed by quantification 
of collagen deposition and the expression of genes involved in liver fibrosis. Similarly, liver 
histology, staining for CD45+ cells and quantification of inflammation-inducible genes 
confirmed an equivalent degree of liver injury in LPS-treated WT and TgHBV mice (Fig.1C 



































































Regarding that several viral proteins may impact on liver disease, it was difficult to 
define the role of HBV AS and related HBSP expression in this experimental model. 
However, the lack of increase in CCl4-induced liver injury in TgHBV mice, expressing the 
complete HBV genome, contrasted with the exacerbations previously observed in transgenic 
mice expressing a subgenomic HBV sequence that is unable to express SP1RNA[20]. 
Considering the high level of SP1RNA in the liver of TgHBV mice, we therefore 
hypothesized that HBV AS, triggered by liver injury could limit the ensuing liver 
inflammation and fibrosis. To understand the role of SP1RNA during liver pathogenesis, we 
first investigated its regulation. 
 
Identification of HBV alternate splicing factors.  
Characterization of pgRNA transregulatory splicing proteins remained a crucial 
prerequisite to investigate HBV AS regulation. Thus, HepG2 nuclear proteins interacting 
with HBV pgRNA were explored by RNA pull-down assay. Identification and relative 
quantification by Orbitrap mass-spectrometry showed in six independent experiments that 
389 proteins were significantly associated with viral pgRNA (Fig.2A and Table S1). 
Classification by gene ontology according to the biological functions allowed to distinct 5 
groups representing 88% of associated-proteins (12% proteins remaining classified in group 
“other”) (Fig.2B). The most significant group was the “RNA processing” family, which was 
mainly composed of factors directly involved in RNA splicing (28/68 proteins; stained in 
Fig.2C). Moreover, 30 additional proteins involved in RNA splicing and comprising hnRNPs 
proteins, were classified in further groups (Table S1). As illustrated, the proteins belonging to 
the “RNA processing” group have additional biological functions, which may contribute to 
the liver disease progression during infectious disease. Specific interaction of 9 



































































in the pgRNA pull-down extract and not in controls (using antisense HBV pgRNA and empty 
beads) by western blot (Fig.2D). The splicing factors SRSF2 and hnRNPH, absent or not 
significantly linked to pgRNA, were used as controls. 
 
Splicing proteins are implicated in the regulation of HBV alternate splicing 
The modulation of expression of HBV pgRNA interacting transregulatory splicing 
proteins (conserved inter-species) was investigated in liver extracts of TgHBV mice. 
Chemical induction of fibrosis led to an overexpression of PSF and SF1 proteins, whilst LPS-
induced liver inflammation increased the expression of SRSF1 and La proteins (Fig.3A). 
Despite the differential signature of splicing factors expression in both liver disease models, a 
comparable increase of SP1RNA proportion was observed. It was considered that AS 
regulation in eukaryotic cells has largely been driven by the alteration of cis-regulatory 
elements. These data provide additional evidence suggesting AS regulation and trans-
regulatory proteins expression according to liver damage [21]. 
Conservation of splicing factors in mammals led us to investigate their involvement 
on HBV AS in vitro. Once different human hepatoma cells were tested, impact of PSF, 
SRSF1 and La expression in viral AS regulation was investigated (Fig.3 B-D). In Huh7 
expressing HBV cells, La and PSF proteins increased SP1RNA proportion, whereas SRSF1 
led to a decrease of viral splicing efficiency (Fig.3E). This paradoxical decrease may be 
attributable to the fact that SRSF1 expression also considerably reduced HBV transcription, 
core and HBeAg expression (Fig.3D), suggesting an impact on HBV RNA synthesis or 
metabolism. Taken together, these data emphasized for a possible influence of the 
microenvironment altered by liver injury on the expression of the HBV-regulatory splicing 





































































HBSP protein partially prevents CCl4-induced liver fibrosis. 
 The impact of the HBV alternative splicing product HBSP on liver pathology was 
investigated in two transgenic mouse strains TgHBSP1&2 expressing the HBSP gene under 
the control of the weak hepato-specific HBx promoter (Fig.S6). The amount of HBSP RNA 
in TgHBSP mice was up to 10 fold lesser than SP1RNA expression in TgHBV mice (1.2x105 
±3.4x104 vs 1.2x106±9.9x105 copies/μg of liver RNAs, respectively) and remained stable 
with aging (FigS5)[15]. Since TgHBSP did not spontaneously develop liver pathogenesis, 
WT and TgHBSP mice were challenged for 2 weeks with CCl4 or TAA to induce liver 
fibrosis (Fig.4A, 4B, S6). Surprisingly, and despite a low fibrosis score (F0/F1) for all mice, 
TgHBSP mice treated with CCl4 or TAA revealed a reduction in collagen deposition 
compared to their WT littermates.  
To evaluate whether HBSP limited the extent of chemically-induced fibrogenesis and 
to investigate its biological impact on advanced stages of liver fibrosis, WT and TgHBSP1 
mice were challenged with CCl4 for 10 weeks (Fig.S6). As expected, all WT treated mice 
displayed severe fibrosis with periportal septa and developed cirrhosis (F4) (n=8/8) (Fig.4C). 
In contrast, TgHBSP1 treated-mice exhibited less marked fibrosis, with 75% animals having 
a F2 (n=2/8) and F3 (n=4/8) fibrosis score and only 25% reaching the F4 cirrhotic state 
(n=2/8). This observation was corroborated by a significant two-fold decrease in collagen 
deposition in TgHBSP1 liver tissue compared to WT mice upon CCl4 treatment (Fig.4C; 
4.5±1.2% vs 8.4±1.2%, p=0.0002, respectively). The expression of pivotal fibrosis-related 
genes Col1a1, Desmin, Timp-1 and MMP-2 confirmed the lower sensitivity of HBSP mice to 
10 weeks CCl4-induced fibrosis (Fig.4D). In accordance with these results, -SMA protein 
expressed by activated hepatic stellate cells (HSCs) was detected in a higher amount in the 



































































Recruitment of immune cells to the liver plays a central role in hepatic 
fibrogenesis[22]. To investigate whether this was altered by the expression of HBSP, 
intrahepatic leucocytes from 10 weeks CCl4-treated mice were isolated and characterized by 
flow cytometry. The CCl4-induced liver leucocyte infiltrate was significantly decreased in 
TgHBSP1 compared to WT mice (Fig.5A). No significant difference in the intrahepatic 
upregulation of CD49b+ NK, CD4+ and CD8+ T (±CD44hi) cells was observed between WT 
and TgHBSP1 mice treated with CCl4 (Fig.5B, 5C). In contrast, the number and proportion of 
liver monocytes/macrophages, defined as CD45+ F4/80+ CD11b+ cells, were significantly 
reduced in TgHBSP1 compared to WT mice treated with CCl4 (Fig.5D; 2.6±0.5x10
5 vs 
4.7±0.5x105 cells, p=0.02 and 14.5±2.1% vs 21.2±1.8% of CD45+, p=0.02, respectively) 
(Fig.5D). In addition, CCl4-challenged WT mice exhibited a higher periportal infiltrate of 
F4/80+ monocytes/macrophages than TgHBSP1 treated mice on stained liver sections 
(Fig.5E).  
Monocytes/macrophages contribute to liver fibrosis through the secretion of 
inflammatory cytokines, which directly activate HSCs[23]. In line with this, we confirmed 
that upon CCl4-induced chronic fibrosis, TgHBSP1 displayed a less pro-fibrotic 
inflammatory environment than WT mice, with a significant decrease in TGF-β, TNF-α and 
IL-1β genes expression (Fig.5F) without differential distribution of monocyte/macrophage 
ontogeny markers CD163 and Marco (Fig.S8) in WT and TgHBSP mice [24]. We next 
investigated the postulate that the decrease in monocyte/macrophage infiltrate in the HBSP-
expressing liver could result from the impaired production of a chemokine involved in 
monocyte/macrophage survival and/or recruitment within the liver[25]. CCL1, CCL2, CCL3, 
CXCL10 and CX3CL1 transcripts were quantified and only CXCL10 and CCL2 were 



































































Together, these results show that HBSP expression restricts partially chronic induced liver 
fibrosis.  
 
HBSP impairs the monocyte/macrophage recruitment during liver injury. 
One explanation for the limited liver pathogenesis observed in TgHBSP1 mice could 
be a resistance of HBSP-expressing hepatocytes to CCl4-induced cytotoxicity. To investigate 
this possibility, WT and TgHBSP1 mice were treated with a single CCl4-injection to induce 
acute liver injury. In the context of acute hepatitis, TgHBSP1 and WT mice displayed 
comparable degrees of liver injury, with a similar increase in circulating ALT and equivalent 
central and periportal necrosis (Fig.6A). The metabolism of CCl4 in hepatocytes leads to 
reactive oxygen species (ROS) production and hepatocyte necrosis through lipid peroxidation 
accumulation. Consistent with this, ROS content assessment on liver extracts revealed a 
similar enhancement in TgHBSP1 and WT treated mice (Fig.6B). In mouse strains, 48h after 
a single CCl4 injection, liver apoptosis was rarely observed compared to necrosis and neither 
Desmin transcripts nor α-SMA protein expression were up-regulated, suggesting that HSCs 
were not yet activated (Fig.S9). Taken together, these results did not support a direct impact 
of HBSP expression on CCl4 hepatocyte toxicity as an explanation for the reduced 
susceptibility of TgHBSP1 mice to liver damage in the chronic exposure model. 
Instead we hypothesised that HBSP expression directly down-regulated hepatocyte 
chemokines content and thus monocyte/macrophage recruitment, accounting for the relative 
resistance to liver fibrosis in TgHBSP1 treated mice. Therefore, monocyte/macrophage 
recruitment was investigated by flow-cytometry in the acute CCl4 hepatitis model. As 
previously observed during chronic exposure, the influx of intrahepatic leucocytes and 
monocytes/macrophages was significantly reduced in HBSP-expressing compared to WT-



































































mice included the inflammatory Ly6Chi CCR2+ subpopulation (Fig.6C right panel: CCl4-WT 
vs CCl4-TgHBSP1: 8.8±0.1x10
5 vs 2.9±0.9x105 cells, p=0.003 and 13.8±2.3% vs 6.9±1.1% 
of CD45+ cells, p=0.01, respectively), recruited through a CCL2-dependent mechanism under 
CCl4 treatment[26]. The diminished recruitment of monocytes/macrophages in TgHBSP1 
acute liver damage was only coupled to a decrease in CCL2 transcripts (Fig.6D) and to a 
down-regulation of CCL2 protein in the liver (Fig.6E). Reduced infiltration of 
monocytes/macrophages, known to be a major source of TNF-α[23], might also account for 
the decrease of TNF-α expression observed. The hepatic cells types producing CCL2 in the 
acute hepatitis model were further explored by immunofluorescence. CCL2 staining revealed 
a high signal around blood vessels and unexpectedly hepatocytes (counterstained by 
cytokeratin 18) were also clearly positive for CCL2 (Fig.6F).  
These data suggested that HBSP expression impacted on liver monocyte/macrophage 
recruitment through a down-regulation of hepatocyte CCL2 expression upon acute liver 
injury.  
 
HBSP modulates CCL2 expression in hepatocytes 
Our results suggested that CCL2 production by hepatocytes contributes to the 
recruitment of monocytes/macrophages and consequently to liver damage. Next, we 
investigated the ability of HBSP to control the expression of CCL2. In line with our previous 
results[15] we showed that p65 (RelA) phosphorylation was impaired in the liver of 
TgHBSP1 compared to WT mice challenged for 10 weeks with CCl4 (Fig.7A). This result 
suggested an impact of NF-B activation on CCL2 expression. Then, we observed in HeLa 
expressing HBSP cells a reduced level of IκBα phosphorylation at 5 minutes after TNF-α, 
treatment (fig.7B, left panel), together with a significant reduction of CCL2 transcription 



































































A significant decrease of CCL2 secretion was also displayed in the supernatant of HepaRG 
expressing HBSP cells treated by TNF-α (Fig.7C left panel; lanes 6 vs 5, respectively: 
24.9±3.7 vs 33.7±2.3 ng/ml; p=0.008). In order to further explore CCL2 modulation by 
HBSP in a whole HBV genome context, a siRNA targeting the SP1RNA encoding HBSP was 
designed. In HBV-transfected HepaRG, siSP1RNA efficiently knocked down SP1RNA (6-
fold decrease compared to scramble siRNA) without cross-reactivity on pgRNA expression 
(Fig.7C middle panel). Upon TNF-α stimulation, CCL2 secretion was significantly higher in 
HepaRG cells in which SP1RNA had been knocked down than in those transfected with a 
scramble siRNA (Fig.7D, lanes 10 vs 9: 46.3±4.0 vs 31.1±1.6 ng/ml, p=0.008).  
To assess whether the reduction of CCL2 expression, through NF-B, in HBSP 
expressing cells may account for the weaker liver fibrogenesis observed in TgHBSP, CCR2 
invalidated (CCR2KO) (n=5) and control (n=5) mice were treated with CCl4. After 2 weeks 
of treatment, picro-sirius staining and western blot analysis of α-SMA expression revealed 
less marked liver fibrosis in CCR2KO mice, highlighting the main influence of this 
chemokine on fibrogenesis (Fig.7E). 
 
CCL2 expression relies on SP1RNA in liver of HBV chronic infected patients  
Several lines of evidence indicate that subjects with CHB have alterations in 
chemokines that may drive pathogenesis[27, 28]. However the contribution of CCL2 
recruitment of monocytes/macrophages has not been addressed in this context. Only few 
studies showed no correlation of circulating CCL2 levels with HBV disease stage but without 
information on CCL2 hepatic expression[28, 29]. Furthermore, although HBV splicing 
regulation was previously suggested during liver disease[8-10, 30], the contribution of 
splicing factors expression was never considered. Therefore we investigated splicing factors 



































































HBV monoinfected treatment-naive patients who were either undetectable or positive for 
HBV SP1RNA (Table S2). All had low-mild liver fibrosis (F0:F1:F2 fibrosis score in 
SP1RNA+ n=1:4:1, in SP1RNA- n=0:6:0) with a high level of HBV RNA expression 
(SP1RNA+ vs SP1RNA- groups: 1.3x107±5.3x106 vs 3.3x106±4.6x106 copies of HBV 
RNA/µg of liver RNA) (Fig.8A). For 3/6 patients from each group, liver sample size allowed 
the additional study of the expression of transregulatory splicing proteins. Despite exhibiting 
a similar stage of liver disease, SP1RNA positive compared to negative liver samples 
displayed a higher expression of hnRNPAB together with La and SRSF1 splicing factors 
(Fig.8B), which were also up-regulated in LPS treated HBV transgenic mice. In SP1RNA 
negative liver samples, La protein expression was mainly observed by immunohistochemistry 
in nucleus while it was increased and gathered in both nuclear and cytoplasmic compartments 
in SP1RNA positive liver samples (Fig.8C), highlighting the shuttling of La protein [31]. 
Regarding CCL2 expression on patient liver sections, a differential staining was noticed with 
an increase in SP1RNA negative hepatocytes (Fig.7D). The level of intrahepatic CCL2 
transcripts was further quantified and SP1RNA positive liver samples displayed a 14 fold 
lower CCL2 expression compared to SP1RNA negative tissues (Fig.8D; 0.13±0.04 vs 
1.87±0.80, p=0.01, respectively).  
 In conclusion, enhancement of transregulatory splicing proteins expression and HBV 
pgRNA splicing in the liver of patients with CHB was associated with a reduction in CCL2 
expression, as previously observed in transgenic mice and in vitro. Our findings support the 
critical role of infected hepatocyte through chemokine production in liver disease and suggest 




































































 Alternate splicing regulation of HBV transcripts was first described more than 20 
years ago but its role in HBV disease has remained poorly defined[4, 5]. The proportion of 
dHBV has been shown to fluctuate considerably in chronic carriers and to be increased with 
the severity of liver pathogenesis[8, 9]. However the regulation of HBV AS and its impact on 
liver immunopathogenesis had not been investigated. 
To decipher the mechanism of post-transcriptional regulation of HBV pgRNA, 
hepatic disease was induced in a HBV transgenic mouse model. In contrast to HBV infection 
models, transgenic mice present the benefice of a stable viral genome variability eliminating 
any potential interference of HBV cis-regulation on pgRNA/protein interactions. This model 
is sufficient to decipher the influence of liver damage on the viral post-transcriptional 
regulation even if the relevance of data obtained on liver pathogenesis is limited due to the 
transgene inducing HBV tolerance and to the constant amount of viral transcripts (including 
SP1RNA) and proteins. Interestingly, we showed that chemical liver damage led to a 
significant increase of HBV AS, suggesting an influence of the microenvironment on the 
splicing machinery. Indeed, the expression of transregulatory splicing proteins interacting 
with HBV pgRNA was affected by liver injuries in mice but also in liver of chronic HBV 
infected patients (Fig.3/8). Transcriptomic analysis from liver diseases samples including 
hepatocarcinoma have previously suggested the role of such dysregulations of AS 
factors[32], here we reported an impact on HBV AS in vitro, in TgHBV mice and in CHB 
liver patients. Whilst the modulation of transregulatory splicing protein expression differed in 
liver inflammation and fibrosis in TgHBV treated mice, both liver damages triggered the 
same activation of viral AS. Characterization of molecular pathways[33] involved in the 
control of trans-regulatory splicing proteins and consequences on genome expression of 



































































The main impact of AS regulation is an enhancement of SP1RNA, which encodes 
HBSP. Unexpectedly, HBSP expression in transgenic mice reduced the liver fibrosis induced 
by chemical treatment. Our results showed that HBSP expression in hepatocytes of treated 
mice downregulated their CCL2 expression and consequently reduced the recruitment of 
monocytes/macrophages. However, an effect on T cells could not be excluded considering 
trends observed in cytometry and cytokines expression data. These tendencies may result 
either from a domino effect on monocyte/macrophage recruitment or from an independent 
direct activity of HBSP on the adaptative immune system. Nevertheless, the direct impact of 
HBSP on hepatocyte CCL2 expression was confirmed in cells expressing HBSP, as well as in 
a whole HBV genome context after SP1RNA knockdown. As previously reported[15], once 
activated by inflammation, the NF-kB signaling pathway is partially hijacked by HBSP and 
as observed in vitro, may account for the downregulation of CCL2 expression. However, 
TgHBV displayed a similar fibrotic disease to WT mice, despite a non-significant 1.4 fold 
decrease of CCL2 expression (data not shown) and enhancement of viral AS. In parallel, 
CCL2-downregulation was found in SP1RNA positive liver patients in HBV chronic carriers 
with comparable liver injury. These data suggest the capacity of HBSP protein to antagonize 
liver fibrogenesis in a dynamic regulation of immune-mediated liver damage during the 
course of HBV infection. 
 Chemokines and their receptors orchestrate the chronology of immune responses 
during liver injury. Among these chemokines, CCL2 plays a central role in the hepatic 
recruitment of activated inflammatory monocytes/macrophages expressing Ly6Chi CCR2+ 
markers[23, 26, 34]. Damaged hepatocytes have previously been suggested to be able to 
produce CCL2[35, 36] but were considered a minor source compared to activated HSCs and 
immune cells[35, 37]. Our data highlight the significant contribution of CCL2 produced by 



































































impact on liver pathogenesis. Therefore, reduced monocyte/macrophage infiltrates may 
account for the differential expression of cytokines and also for the recruitment of other 
immune cells in 10 weeks CCl4-treated mice, which seemed also partially affected, compared 
to control mice. Nevertheless, the main role of CCL2 downregulation was supported by the 
data obtained from the single CCl4-injection in TgHBSP mice as well as the similar 
impairment of liver fibrosis to those observed in CCR2KO treated mice, although altered 
immune composition at baseline may limit conclusion for this last model. Influence of 
monocytes/macrophages during HBV pathogenesis has been poorly explored even if the 
modulation of noncytolytic antiviral activity via their cytokine secretion was reported [38-
40]. Additionally, monocytes/macrophages could participate in HBV specific adaptive 
immunity through the formation of intrahepatic myeloid-cell aggregates enabling local CD8+ 
T cells expansion (iMATEs)[41, 42]. Thus, by countering monocyte/macrophage recruitment, 
HBSP might support the maintenance of a tolerogenic environment and favour immune 
escape[43]. Furthermore, the relationship between CCL2 and human HCC survival 
emphasized the clinical observation of HBV splicing enhancement prior to development of 
HCC and speculate about the role of HBSP in liver disease progression [44]. 
Strengthened by previous clinical data reporting an increase of HBV defective 
circulating particles related to SP1RNA with liver disease severity[8-10], our present study 
suggests a new feedback loop involving HBV AS to counteract liver injury. As proposed in 
Figure 8E, the hepatic microenvironment altered by liver damage may contribute to enhance 
splicing factors involved in HBV SP1RNA production, and thus HBSP expression. 
Hepatocytes expressing HBSP exhibit reduced CCL2 secretion and consequently attenuated 
monocyte/macrophage recruitment, thereby constraining inflammation. Although speculative 
at this stage, it is possible that hepatocytes expressing HBV SP1RNA are preferentially 



































































persistence during chronic liver injury. To date, whether efficient viral suppression by 
antiviral therapy is accessible for the management of HBV infection, eradication of 
intracellular virus remains a challenge. CCL2 targeted immunotherapy in combination with 
nucleoside analog should contribute to facilitate an efficient HBV cure through a disruption 
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Fig.1: Liver injury increases HBV pgRNA alternate splicing in HBV transgenic mice 
(A) HBV pgRNA and SP1RNA expression (left) and SP1RNA proportion (right) quantified 
in the liver of TgHBV mice treated with oil/CCl4 for 7 weeks or with PBS/LPS for 2 weeks. 
(B) Representative H&E and Picro-Sirius red stained histological liver section (left, bar 
250μm) and quantification of collagen deposition (right) from 7 weeks oil, CCl4-WT and 
CCl4-TgHBV treated mice (upper panel). Fibrosis-related mRNA expression in the liver, 
each dot represents a mouse, experiments were performed on oil-WT (n=7), oil-TgHBV 
(n=7), CCl4-WT (n=9) and CCl4-TgHBV (n=8) mice (lower panel). C) Representative H&E 
histological staining (upper, bar: 250μm); CD45 and Cytokeratin 18 (CK18) 
immunofluorescence staining on liver section (lower, bar: 50μm) from 2 weeks PBS, LPS-
WT and LPS-TgHBV treated mice (upper panel). Cytokines mRNA expression in the liver of 
2 weeks PBS or LPS-treated WT and TgHBV mice. Each dot represents a mouse; 
experiments were performed on PBS-WT (n=6), PBS-TgHBV (n=7), LPS-WT (n=5), and 
LPS-TgHBV (n=5) treated-mice (lower panel). Mann-Withney U-tests: *p<0.05, **p<0.01 
and ***p<0.001. 
 
Fig. 2: Identification of cellular splicing factors interacting with HBV pgRNA 
(A) Volcano plot representation of HBV pgRNA-interacting proteins (700/1442) detected in 
6 independent RNA pull-down assays (beads used as control) and identified by mass 
spectrometry (nanoRSLC-LTQ Orbitrap Velos). Proteins showing a significant interaction 
with HBV pgRNA (n=389/700) are depicted uppers the black line according to significance 
analysis. X-axis shows the difference of the average of the logarithm of Label Free 



































































logarithmic of t-test Welsh p-value. (B) Biological function groups of HBV pgRNA binding 
proteins identified. (C) Schematic network presenting the main protein families binding to 
HBV pgRNA according to Ingenuity software. Transregulatory splicing factors are colored in 
blue and the ones selected for further characterization are colored in pink. (D) HBV pgRNA 
pull-down extract analysis by western blot confirming a specific interaction of 9 selected 
trans-regulatory splicing factors with pgRNA (antisense pgRNA (asRNA), beads and SRSF2 
protein were used as negative control). 
 
Fig. 3: SP1RNA regulation is dependent on splicing-proteins expression 
(A) Splicing regulatory proteins expression in the liver of TgHBV mice treated with oil/CCl4 
for 7 weeks or with PBS/LPS for 2 weeks (SRSF2 and hnRNPH1 used as controls). (B) 
SP1RNA proportion (SP1RNA/(SP1RNA+pgRNA)x100) in Huh7, HepG2 and HepaRG cells 
expressing HBV after transient transfection of pHBV vector. (C) Huh7 co-tranfected cells 
with pHBV and PSF-GFP or SRSF1-GFP; PSF-GFP and SRSF1-GFP visualization and 
nucleus were counter stained with Hoescht (middle, bar 50μm); (D) pgRNA and SP1RNA 
quantification in HBV expressing Huh7 cells co-transfected with Neo (control), PSF, La or 
SRSF1 plasmids (left panel), and (right panel) HBV SP1RNA proportion in these cells (n≥3 
experiments). (E) HBeAg cell supernatant quantification (left panel) and PSF, SRSF1, La and 
Core expression by western blot (right panel). Mann-Withney U-tests: *p<0.05, **p<0.01 
and ***p<0.001. 
 
Fig.4: HBSP expression protects against chemical-induced liver fibrosis 
Representative H&E and Picro-Sirius red stained histological liver section (bar 250μm) (left) 
and quantification of collagen deposition (right) from: (A) WT, TgHBSP1 and TgHBSP2 



































































TgHBSP2 (n=7) mice. (B) WT and TgHBSP1 mice treated for 2 weeks with PBS (n=4 for 
both) or TAA-WT (n=7) and TAA-TgHBSP1 (n=8) mice. (C) WT and TgHBSP1 mice 
treated for 10 weeks with oil (n=6 for both WT and TgHBSP1) or CCl4 (n=8 for both WT 
and TgHBSP1). (D) Liver fibrosis-related gene mRNA and α-SMA protein expression in the 
liver of WT and TgHBSP1 mice treated for 10 weeks with oil or CCl4. Each dot represents a 
mouse. Mann-Withney U-tests: *p<0.05, **p<0.01 and ***p<0.001. 
 
Fig.5: HBSP expression reduces intrahepatic monocytes/macrophages infiltrate 
WT and TgHBSP1 mice were treated for 10 weeks with oil or CCl4. Intrahepatic leucocytes 
were isolated and analysed by flow cytometry. (A) Intrahepatic leucocyte cells number (left) 
and representative gating of CD4+ and CD8+ T cells (right). (B) CD4+ T (7-AAD-
,CD3+,TCRβ+,CD4+) and CD44hi effector/memory CD4+ T cells number. CD8+ T (7-AAD-
,CD3+,TCRβ+,CD8+) and CD44hi effector/memory CD8+ T cells number (left). (C) NK (7-
AAD-,CD49b+,CD3-) cells number and representative gating. (D) Intrahepatic 
monocytes/macrophage cells number, proportion and representative gating of (7-AAD, 
CD45+, F4/80+, CD11b+) from WT and TgHBSP1 CCl4-treated mice (right). (E) 
Representative monocytes/macrophages F4/80 staining on histological liver section (bar 
250μm). (F) Cytokines (upper panel) and chemokines (lower panel) mRNA expression in the 
liver. Each dot represents a mouse; experiments performed on 10 weeks oil-WT (n=6), oil-
TgHBSP1 (n=6), CCl4-WT (n=8) and CCl4-TgHBSP1 (n=8) treated mice. Mann-Withney U-
tests: *p<0.05, **p<0.01 and ***p<0.001. 
 
Fig.6: HBSP has no impact on CCl4-induced hepatocyte acute damage but decreases 



































































WT and TgHBSP1 mice treated with a single injection of oil or CCl4. (A) Sera ALT and liver 
necrotic tissue quantification on H&E stained histological section, representative H&E 
staining are presented (upper: bar 500μm; lower: bar 250μm). (B) ROS staining on liver 
frozen section (left, bar 100μm) and ROS content quantification in liver extract with H2-
DCFDA probe (right). (C) Intrahepatic cells number (left) and proportion of 
monocytes/macrophages (middle; 7-AAD, CD45+, F4/80+, CD11b+) and pro-inflammatory 
Ly6Chi CCR2+ subpopulation (right). (D) Liver cytokines and chemokines mRNA 
expression. (E) CCL2 quantification in liver protein extract. (F) CCL2 and CK18 
immunofluorescence staining on liver sections, nucleus were labelled with Hoescht (bar 
50μm). Each dot represents a mouse; experiments were performed on oil (n=6), CCl4-WT 
(n=7) and CCl4-TgHBSP1 (n=10) single injected mice. Mann-WithneyU-tests: *p<0.05, 
**p<0.01 and ***p<0.001. 
 
Fig.7: Association between SP1RNA, HBSP and CCL2 expression in vitro 
(A, left panel) Western blot detection of p65 (RelA) total and its phosphorylated form (P-p65) 
on Ser536 in liver of TgHBSP and control mice treated by vehicle or CCl4 during 10 weeks. 
(A, right panel) Quantification of P-p65 related expression in liver of TgHBSP and control 
mice treated by vehicle (n=4), by CCl4 during 10 weeks in control (n=3) and TgHBSP (n=3) 
mice. (B, left panel) Total IκBα and phosphorylation level in HeLa cells transfected with 
pNeo or pHBSP plasmids and treated with TNF-α (25ng/ml) for 0, 5, 15 minutes. (B, right 
panel) Relative CCL2 mRNA quantification (normalized with GAPDH) by RTqPCR 
measured in HeLa expressing HBSP or control (pNeo) cells and treated or not with TNF-α 
(25ng/ml) during 30 minutes (n=5 experiments). (C, left panel) Secreted CCL2 protein 
quantification by HepaRG cells (stimulated or not with 50 ng/ml TNF-α) expressing pNeo 



































































SP1RNA quantification from HepaRG cells co-transfected with pHBV plasmid and scramble 
(siSc) or SP1-siRNA (siSP1) (n=7 experiments). (D) Secreted CCL2 protein quantification 
by HepaRG cells (stimulated or not with TNF-α) expressing pNeo or pHBV plasmid with 
siSc or siSP1-siRNAs (n=6 experiments). (E, upper left panel) Representative H&E and 
Picro-Sirius red stained histological liver section (bar 2mm) and (E lower left panel) focus of 
Picro-Sirius red stained (bar 800µm) of WT and CCR2Ko mice treated for 2 weeks with 
CCl4-WT (n=) and CCl4. (E right panel) Fibrosis-related α-SMA protein expression in the 
liver of WT and CCR2KO mice treated for 2 weeks with oil (n=2) or CCl4 (WT with n=4 out 
of 5 and CCR2KO with n= 4 out of 5). Mann-Withney U-tests: *p<0.05 and **p<0.01. 
 
Fig.8: Association between SP1RNA, CCL2 and transregulatory splicing factors in 
HBV chronic carriers 
(A) HBV RNA and SP1RNA quantification in the liver of HBV chronic carriers (n=6 for 
undetectable (Und.) and n=6 for detectable SP1RNA groups). (B) Splicing factors expression 
in the liver of HBV chronic carriers with undetectable or detectable SP1RNA. (C) La and 
CCL2 immunochemistry on serial liver section counterstained with hematoxylin (upper and 
lower bar 50μm) from chronic HBV carrier with undetectable or detectable SP1RNA. (D) 
CCL2 mRNA quantification in the liver of HBV chronic carriers with undetectable (n=6) or 
detectable SP1RNA (n=6). (E) Schematic model for SP1RNA synthesis and HBSP activity 
during liver damage. Under liver damage SP1RNA/HBSP expressing hepatocyte through 
decreasing liver inflammatory microenvironment have a selective advantage leading to the 
increase of SP1RNA proportion during the course of HBV infection. Mann-Withney U-tests: 


































































































































































































































































































































































function pmin pmax protein
RNA processing 3.9 10-4 4.3 10-53 68
Protein synthesis 3.2 10-6 1.1 10-17 58
Cancer 4.9 10-1 1.4 10-17 315
Organismal injury 1 10-0 1.4 10-17 326

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pNeo - - -++ -






































































































HBV RNA copies/μg RNA






























































































Graphical abstract : Hepatocytes expressing HBSP could be preferentially 
maintained during HBV chronic active infection 
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